

July 2008 PBAC OUTCOMES - Deferrals

DRUG AND FORM	DRUG USE AND TYPE	LISTING REQUESTED BY SPONSOR	PBAC OUTCOME AND COMMENT
Dasatinib, tablet, 20 mg, 50 mg, 70 mg, (Sprycel [®]) Bristol-Myers Squibb Pharmaceuticals Minor submission	Chronic myeloid leukaemia (CML) Acute lymphoblastic leukaemia (ALL)	To request the removal of the 140 mg/day dosage restriction for both CML and ALL.	Deferred, pending further information.
		Sponsor's comments:	The sponsor will continue to work with the PBAC to reach a satisfactory outcome.